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Abstract
 
Epstein Barr virus (EBV)
 
  
 
Hodgkin’s disease (HD) expresses clearly identified tumor antigens
derived from the virus and could, in principle, be a target for adoptive immunotherapy with
viral antigen–specific T cells. However, like most tumor-associated antigens in immunocom-
petent hosts, these potential targets are only weakly immunogenic, consisting primarily of the
latent membrane protein (LMP)1 and LMP2 antigens. Moreover, Hodgkin tumors possess a
range of tumor evasion strategies. Therefore, the likely value of immunotherapy with EBV-
specific cytotoxic effector cells has been questioned. We have now used a combination of gene
marking, tetramer, and functional analyses to track the fate and assess the activity of EBV cyto-
toxic T lymphocyte (CTL) lines administered to 14 patients treated for relapsed EBV
 
  
 
HD.
Gene marking studies showed that infused effector cells could further expand by several logs in
vivo, contribute to the memory pool (persisting up to 12 mo), and traffic to tumor sites. Tetramer
and functional analyses showed that T cells reactive with the tumor-associated antigen LMP2
were present in the infused lines, expanded in peripheral blood after infusion, and also entered
tumor. Viral load decreased, demonstrating the biologic activity of the infused CTLs. Clini-
cally, EBV CTLs were well tolerated, could control type B symptoms (fever, night sweats, and
weight loss), and had antitumor activity. After CTL infusion, five patients were in complete re-
mission at up to 40 mo, two of whom had clearly measurable tumor at the time of treatment.
One additional patient had a partial response, and five had stable disease. The performance and
fate of these human tumor antigen–specific T cells in vivo suggests that they might be of value
for the treatment of EBV
 
  
 
Hodgkin lymphoma.
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Introduction
 
Immunotherapy with CTLs has successfully prevented and
treated EBV-associated lymphoproliferative diseases occurring
after hematopoietic stem cell and solid organ transplants
(1–8). EBV lymphoproliferative diseases are generally highly
immunogenic, express all of the EBV latent antigens (type
3 latency), and arise only in patients with severe T cell dys-
function. By contrast, EBV
 
  
 
Hodgkin’s disease (HD) arises
in the immunocompetent host and must evade preexisting
immune responses to EBV, which control virus-infected
normal B cells and epithelial cells. Hence, the malignant
Reed-Sternberg cells of HD have developed a multiplicity
of immune evasion mechanisms (9), including the down-
regulation of the immunodominant EBV nuclear antigen
(EBNA)3A, EBNA3B, and EBNA3C antigens to which
the bulk of the CTL response to latent antigens is directed.
Nevertheless, the tumor cells continue to express the im-
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PCR; SCT, stem cell transplant; SFC, spot-forming cell. 
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munologically subdominant viral latency proteins latent
membrane protein (LMP)1 and LMP2, and are therefore
potential targets for immunotherapy with EBV-specific
CTLs. Because patients with HD have a high rate of mor-
bidity after conventional treatment and a poor prognosis af-
ter relapse (10, 11), we decided to explore the value of
EBV CTL therapy for this disease.
EBV CTLs were generated using patient-derived EBV-
transformed B lymphocytes (B lymphoblastoid cell lines
[LCLs]) as APCs. These LCLs predominantly induce pro-
liferation of T cells specific for the early lytic cycle transac-
tivators BZLF1 and BMLF1 and for the latency-associated
EBNAs (3A, 3B, and 3C), which are antigens that are not
expressed by the EBV
 
  
 
tumor cells of HD (12). However,
LCLs also reactivate T cells specific for LMP2, an EBV la-
tency antigen regularly expressed by the tumor (13, 14).
We hypothesized that any clones recognizing tumor-asso-
ciated antigens would expand in vivo (15). To track the in
vivo persistence and fate of the infused EBV CTLs, we ge-
netically marked the CTLs of some patients by transduc-
tion with a retroviral vector expressing the neomycin resis-
tance (
 
neo
 
) gene (2, 16) and analyzed the numbers of LMP-
2–reactive cells using tetramers and functional assays. In pa-
tients with measurable disease, we also assessed the impact
of the CTLs on tumor burden. Our results showed both in
vivo expansion and persistence of tumor-reactive T lym-
phocytes and evidence that these cells can have substantial
antitumor activity.
 
Materials and Methods
 
Patients and EBV Status of the Tumors.
 
The investigation was
approved by the Food and Drug Administration, the Recombi-
nant DNA Advisory Committee, and the hospitals’ Institutional
Review Boards. Of our referrals, 26% had tumors that were pos-
itive for EBV. 13 patients were treated on these protocols in the
USA, and 1 was treated in Germany after regulatory approval in
that country (Table I). Patients were eligible if they had received
treatment for relapsed HD and had been off other systemic lym-
phoma therapy for 1 mo before CTL infusion and had either
measurable disease or were considered at high risk of relapse. In
 
Table I.
 
Patient Characteristics
 
Patient
ID Age Sex
Disease stage
at diagnosis
Most recent chemo
(time before CTL)
Gene
marked
Dose
level
Toxicity
attributed to CTL Response to CTL Outcome
1 21 M IA SCT
 
→
 
relapse 5 mo
later
 
→
 
CTL (8 mo)
Yes 1 None Stable disease DOD 13 mo after CTLs
2 18 M IVB 3 wk hemipelvis RT
(stopped 1 d before CTL no. 2)
Yes 1 None Stable disease
(hilar/mediastinal/
pulmonary)
DOD 10 mo after CTLs
3 24 M IIIA Vinblastine weekly (1 mo) Yes 1 Transient
malaise
PR DOD 12 mo after CTLs
43 6 F I I
 
E
 
A Paraspinal RT and 
 
 
 
IFN (1 mo) Yes 1 None NR DOD 2 mo after CTLs
5 19 F IIIA Mantle/lung RT (1 mo) Yes 1 None Stable disease DOD 10 mo after CTLs
6 36 M IIIA MOPP (2 mo) Yes 1 None Stable disease
then allo BMT
In remission 56 mo
after CTLs
7 40 F IIIB ABVD (2 mo) No 2 None Stable disease DOD 20 mo after CTLs
8 24 M IIA MTX and 6TG (2 mo) Yes 2 None NR DOD 7 mo after CTLs
9 20 M IVB SCT (10 mo) No 1 None Remains in remission In remission 24 mo
after CTLs then lost to
follow-up
10 27 F IIB SCT (4 mo) RT (2 mo) No 1 None CRU
 
a
 
In remission 24 mo
after CTLs
11 16 M IIB SCT (2 mo) 
 
 
 
IFN (1 wk) No 1 None CRU
 
a
 
In remission 38 mo
after CTLs
12 18 M IIA SCT (3 mo) No 2 None CR In remission 27 mo
after CTLs
13 29 F IIB SCT (3 mo) No 2 None NR DOD 4 mo after CTLs
14 8 F IA RT (9 mo) No 2 Transient swelling
and pain in cervical
lymph node
CR In remission 9 mo after CTLs
 
DOD, died of disease; PR, partial response; NR, no response; CR, complete response; CRU, complete remission undetermined; RT, radiotherapy;
MOPP, mechlorethamine, oncovin (vincristine), procarbazine, and prednisone; ABVD, adriamycin, bleomycin, vinblastine, and dacarbazine; MTX,
methotrexate; 6TG, 6-thioguanine.
 
a
 
These two patients had residual mediastinal masses after autograft at the time they received CTLs, which eventually resolved but could not be classi-
fied as having definite disease, as gallium scans were negative. 
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all patients, tumor samples had been established as EBV
 
  
 
using
immunohistochemistry for LMP-1 and/or in situ hybridization
for the small nonpolyadenylated viral RNA (EBV-encoded small
RNA [EBER]1; reference 14).
 
Generation of EBV-transformed B Cell Lines.
 
After consent, the
patients donated 40–70 cc peripheral blood. 5–10 
 
  
 
10
 
6 
 
PBMCs
were used for the establishment of an EBV-transformed LCL
(EBV-LCL) by infection of PBMCs with concentrated superna-
tants from the B95-8 working cell banks (17). EBV-LCLs were
grown for at least 2 wk in acyclovir before being used as APCs to
prevent the release of infectious virus. This treatment targets the
virus thymidine kinase and inhibits lytic virus production, but does
not affect the expression of the early lytic cycle transactivators.
 
Generation of EBV-specific CTL Cultures.
 
To generate EBV-
specific CTLs, PBMCs were cocultured with 
 
 
 
-irradiated (40 Gy)
autologous LCLs at a responder/stimulator ratio of 40:1 in a 24-
well plate. Starting on day 10, the responder cells were restimu-
lated weekly with irradiated LCLs at a responder/stimulator ratio
of 4:1. Two weekly doses of rhIL-2 (R&D Systems) were added
from day 14. CTL lines were cultured in complete medium
(RPMI 1640 medium; GIBCO BRL or Hyclone) containing
10% FCS (Hyclone), and 2 mM 
 
l
 
-glutamine (
 
n 
 
  
 
11; Biowhit-
taker), or complete medium supplemented with 45% EHAA (
 
n 
 
 
 
3; Irvine Scientific). To increase the rate of expansion when the
cell line was growing poorly, 12 CTL lines were treated with a
“superexpansion cocktail” consisting of irradiated allogeneic
PBMCs from blood bank–approved donors, irradiated autologous
EBV-LCL, 50 ng/mL anti-CD3 (Orthoclone OKT3; Ortho Bio-
tech), and 100 U/mL IL-2 (14). To avoid
 
 
 
stimulating allospecific
clones, this cocktail was used only from the third stimulation.
 
Gene Marking of EBV-specific CTLs.
 
Seven patients received
CTLs genetically marked by transduction with the G1Na (five
patients) or LNSJ1 (two patients) retroviral vectors, which con-
tain the 
 
Escherichia coli
 
–derived
 
 
 
neomycin resistance gene (
 
neo
 
).
Clinical grade G1Na or LNS-containing
 
 
 
supernatant from a
PA317 amphotropic packaging cell line (provided by Genetic
Therapy Inc.) was incubated for 6 h with the
 
 
 
CTLs at a multiplic-
ity of infection of 10:1 in the presence of 50–100 U/mL IL-2 and
4 
 
 
 
g/mL protamine sulfate in a 75-cm
 
2 
 
flask (14). After transduc-
tion, the CTLs were returned to their regular growth schedule.
To determine the efficiency of transduction, DNA was extracted
from an aliquot of the transduced cells and analyzed by real-time
PCR as described below. Transduction efficiencies ranged from
1.01 to 15.6%.
 
Cytotoxicity Assays.
 
The cytotoxic specificity of each CTL
line was analyzed in a standard 4-h chromium-51 release assay us-
ing effector/target ratios
 
 
 
of 40:1, 20:1, 10:1, and 5:1 (3). The fol-
lowing target cells were tested: autologous LCL; HLA class I–
and II–mismatched LCL; HSB-2, which
 
 
 
is sensitive to killing by
lymphokine-activated killer cells; and autologous lymphoblasts
that had been stimulated with PHA blasts (17). To determine
whether the EBV-specific CTL lines recognized the EBV anti-
gens expressed by
 
 
 
Hodgkin’s cells, the killing of target cells ex-
pressing LMP2 or LMP1 alone was tested. Autologous or HLA-
matched dermal fibroblast lines were treated for 24 h with IFN-
 
 
 
to increase the expression of MHC molecules and infected for 48
h with recombinant adenovirus containing
 
 
 
either LMP2a or GFP
genes (provided by A. Davis, Baylor College of Medicine, Hous-
ton, TX; reference 18). The chromium release assay was har-
vested after 6 h.
 
Immunophenotyping.
 
CTL lines were stained with CD3,
CD4, CD8, CD16, CD56, TCR 
 
  
 
, TCR 
 
  
 
, CD19, CD62L,
CD45RA, and CD45RO (Becton Dickinson). For V
 
  
 
usage,
cells were stained with perCP anti-CD3 (Becton Dickinson) and
PE- or FITC-conjugated anti-V
 
  
 
mAbs (Beckman Coulter). For
each sample, 10,000 cells were analyzed by FACSCalibur using
CELLQuest software (Becton Dickinson).
 
Tetramer Staining.
 
To detect LMP2 peptide–specific T cells
in the CTL lines and PBMCs, soluble HLA-A02
 
*
 
01-CLG-
GLLTMV, HLA-A02
 
*
 
01-FLYALALLL, HLA-A11
 
*
 
01-SSCSSCP-
LSKI, HLA-A24
 
*
 
01-PYLFWLAAI, HLA-A24-TYGPVFMSL,
and HLA-B35
 
*
 
01-MGSLEMVPM PE-conjugated tetramers were
prepared by the National Institute of Allergy and Infectious Dis-
eases Tetramer Core Facility and by the Baylor College of Medi-
cine Tetramer Core Facility. The peptides were synthesized
either by M. Campbell (University of Texas Anderson Cancer
Center, Houston, TX) or by Genemed Synthesis Inc. 5 
 
  
 
10
 
5
 
CTLs or 10
 
6 
 
PBMCs were incubated at room temperature for 30
min in PBS with 1% FCS containing the PE-labeled tetrameric
complex, anti-CD8 FITC, and anti-CD3 PerCP. IgG-PE was
used for isotype control. Stained cells were fixed in PBS contain-
ing 0.5% paraformaldehyde. For each sample, 100,000 cells were
analyzed as described above.
 
Monitoring of Gene-marked T Cell Lines In Vivo.
 
The forward
and reverse primers and probe sequences specific for the G1Na
vector were CAGCCCTCACTCCTTCTCTAGG, CGAAAC-
GATCCTCATCCTGTCTCTTG (GIBCO BRL), and CCG-
CTACAATTCC, respectively (Applied Biosystems). The for-
ward and reverse primers and probe sequences specific for LNSJ1
vector were CCCTTTATCCAGCCCTCACTCC, CTCATC-
CTGTCTCTTGATCAGATCGG, and TCTAGGCGCCGG-
AAT, respectively. The G1Na and LNSJ1 probes were 5
 
  
 
VIC
and 3
 
  
 
MGBHQ conjugated (Applied Biosystems). The forward
and reverse primers and probe sequences specific for C-reactive
protein gene (used as the internal control) were CTTGAC-
CAGCCTCTCTCATGC, TGCAGTCTTAGACCCCACCC,
and TTTGGCCAGACAGGTAAGGGCCACC, respectively.
C-reactive protein probes were 3
 
  
 
FAM and 5
 
  
 
MGBHQ conju-
gated (Applied Biosystems). A standard was generated from K562
cells transduced with each vector with a single retroviral integrant
diluted with nontransduced K562 cells to the following clinically
relevant dilution range: 0.01, 0.069, 0.29, 1.27, 5.4, 33, and
100%. 250 ng genomic DNA was used as the template with Taq-
Man PCR mastermix (Applied Biosystems) diluted to 1
 
  
 
with
nuclease-free water. Thermocycling and fluorescent analysis was
performed with ABI PRISM 7700 (Applied Biosystems; refer-
ence 19). FAM and VIC signals were measured simultaneously.
Real-time fluorescence measurements were taken, the threshold
cycle value for each sample was calculated by determining the
point at which the fluorescence exceeded a threshold limit, and
the percentage of transduced cells was calculated from the stan-
dard curve.
 
Detection of EBV DNA in PBMCs by Quantitative Real-Time
PCR (Q-PCR).
 
DNA was isolated from 3–5 
 
  
 
10
 
6 
 
PBMCs us-
ing an anion exchange column (QIAGEN). 500 ng DNA was
analyzed by Q-PCR as described previously (20) to quantitate
EBV genome copy number per microgram.
 
In Situ Hybridization for neo.
 
To document the presence of
gene-marked, EBV-specific T cells in tumor tissue, we examined
paraffin sections of tumor for 
 
neo-
 
bearing cells using in situ PCR
as described previously (3). Paraffin-embedded Burkitt’s lym-
phoma cell line (BL2) and G1Na-transduced K562 served as neg-
ative and positive controls, respectively.
 
ELISPOT Assay.
 
ELISPOT analysis was used to quantitate
the frequency of LMP2 peptide–specific CTLs or to compare the
peripheral blood T cells responding to LCLs or peptide-pulsed 
Cytotoxic T Cells for EBV
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PHA blasts by IFN-
 
  
 
secretion before and after CTL infusion.
All studies for each patient were performed in one single assay us-
ing batched-frozen PBMCs to avoid interassay variability. LCLs
or autologous PHA blasts alone or pulsed with the LMP2 pep-
tides MGSLEMVPM (MGS) or SSCSSCPLSKI (SSC) were used
as stimulators. As controls, PBMCs were stimulated with 1 
 
 
 
g/
ml staphylococcal enterotoxin B (Sigma-Aldrich) and 1 
 
 
 
g/ml
CMV lysate (Advanced Biotechnologies), or PHA blasts were
pulsed with CMV peptides NLVPMVATV (A02
 
*
 
01 restricted)
or TPRVTGGGAM (B07
 
*
 
01 restricted) in patients with the ap-
propriate HLA types.
Stimulators were irradiated (40 Gy), washed, and then resus-
pended at 2 
 
  
 
10
 
5
 
/ml. Responder PBMCs were thawed 24 h be-
fore assay set-up, cultured in CTL media (without IL-2), and
then harvested and resuspended at 2 
 
  
 
10
 
6
 
/ml. 96-well filtration
plates (MultiScreen, no. MAHAS4510; Millipore) were coated
with 10 
 
 
 
g/mL anti–IFN-
 
  
 
antibody (Catcher-mAB91-DIK;
Mabtech) overnight at 4
 
 
 
C and then washed and blocked with
ELISPOT medium for 1 h at 37
 
 
 
C. Responder and stimulator
cells were incubated on the plates for 20 h. The plates were then
washed and incubated with the secondary biotin-conjugated
anti–IFN-
 
  
 
mAb (Detector-mAB [7-B6-1-Biotin]; Mabtech)
followed by incubation with avidin–biotinylated horseradish per-
oxidase complex (Vectastain Elite ABC Kit [Standard], no.
PK6100; Vector Laboratories), and then developed with AEC
substrate (Sigma-Aldrich; reference 21). Plates were sent for eval-
uation to Zellnet Consulting. Spot-forming cells (SFCs) and in-
put cell numbers were plotted.
 
Patient Characteristics.
 
14 patients received CTLs (Table I). Of
these patients, 12 had nodular sclerosing HD and 2 had mixed cel-
lularity. Their ages ranged from 8 to 40 yr, and their initial disease
presentation ranged from stage IA to IVB (22). Samples for CTL
generation were collected from patients after a first or subsequent
relapse. Nine patients received CTL doses of 4 
 
  
 
10
 
7 
 
cells/m
 
2
 
,
 
 
 
and
five received 1.2 
 
  
 
10
 
8 
 
cells/m
 
2 
 
(Table I). As shown in Table I, all
except patient 2 received CTL therapy at least 4 wk from other
chemotherapy/radiotherapy or at least 2 mo from stem cell trans-
plant (SCT). Patient 2 had extensive disease with bone, hilar, me-
diastinal, and pulmonary involvement and was receiving localized
radiotherapy to the right hemipelvis for pain control during his
course of CTL therapy. The hemipelvis was not included in our
evaluation of disease response after CTL therapy. Analysis of dis-
ease response to CTL therapy was performed using standard East-
ern Cooperative Oncology Group criteria (23).
 
Results
 
CTL Line Characteristics
EBV-specific CTL Lines Contained LMP2-specific T Cell
Populations on Tetramer Analysis.
 
CTL lines from patients
grew more slowly than lines from healthy controls and
required frequent mitogenic stimulation. However, they
were ultimately indistinguishable by immunophenotype
and cytolytic activity from lines generated from normal in-
dividuals based on the phenotypic markers CD3, CD4,
CD8, CD56, TCR 
 
  
 
, and TCR 
 
   (Table II and refer-
ence 14). The patient EBV CTL also had an effector–
memory phenotype (CD62L  CD45RA  CD45R0 ; ref-
erences 14 and 24–27). Analysis of v  expression by flow
cytometry (Fig. 1) did not reveal any stereotyped pattern of
v  usage in CTL lines from normal individuals or Hodgkin
patients (six of each illustrated). Nor was there any differ-
ence in the frequency of T cells specific for well-character-
ized LMP2 epitopes in CTL lines from patients or healthy
controls. Table II shows flow cytometric analysis per-
formed on patients with informative HLA types. HLA-
A02*01, -A11, -B35, and -A24 LMP2 tetramers bound to
 1–6% (median 0.75%) of the CD8 T cells in CTLs from
six normal EBV-seropositive donors and to  1–6.8% (me-
Table II. CTL Line Characteristics
Patient ID
CD3 /CD4 
(%)
CD3 /CD8 
(%)
TCR   /CD3 
(%)
TCR   /CD3 
(%)
CD56 /CD3 
(%)
LMP2 tetramer
positivity HLA type
1 10 91 99 1.3 5.5 not tested A3;11/B27;51
2 3 94 85 0.3 4 not tested A2;3/B44;62
3 15 56 72 1.9 25 yes A2;3/B18;35
4 1.5 85 96 0.9 9 not tested A3/B7;40(61)
5 17 84 61 34 15 not tested A3;24/B7
6 1.2 98 98 1.2 0.7 yes A2;3/B7;51
7 15 58 48 45 16 yes A2;32/B18;71
8 0.1 99 99 0.1 29 yes A2;3/B7;18
9 3 78 51 57 5 no A31;68/B35;39
10 38 63 90 7 34 yes A1;24/B18;53
11 0.6 95 95 12 1.8 yes A1;68/B35;81
12 1 98 96 2.5 0.7 yes A11;29/B7;40(61)
13 49 39 86 15 0.1 yes A1;24/B35;61
14 24 54 83 15 0.8 no A2;26/B44;50
HLA specificity of the tetramer is highlighted in bold.Bollard et al. 1627
dian 1.03%) of the CTLs from Hodgkin patients (Fig. 2). A
broad range of epitopes were recognized by patient lines,
although there was a particularly high representation of the
B35-restricted LMP2 epitope MGS in the CTL line gener-
ated from patient 11. Flow cytometric analysis was also
performed on CTL lines from HLA-A02*01 patients using
available HLA-A02*01–restricted LMP1 and HLA B07*01–
restricted EBNA1 tetramers, but no detectable LMP1 or
EBNA1-specific populations were identified. Therefore, the
frequency of LMP2-specific effectors in the CTL lines
generated from HD patients was not significantly different
from the frequency seen in the CTL lines generated
from normal donors (P   0.16). This result is unexpected.
LMP2-specific T cells are readily detectable by tetramer
and ELISPOT analysis in the peripheral blood of healthy
donors but appear to be absent in HD patient blood.
Therefore, we assume that growth and survival of LMP2-
specific T cells is compromised in patients in vivo but might
be restored during ex vivo culture (9).
In Vivo Behavior of Adoptively Transferred EBV-specific 
CTL Lines
Infused CTLs Expand In Vivo, Persist in the Circulation, and
Traffic to Sites of Tumor. Seven patients received CTLs
that had been genetically marked with a retrovirus contain-
ing the neomycin resistance gene (neo; reference 3). Neo 
cells were then tracked in the peripheral blood using
Q-PCR. Gene-marked CTLs could be detected in PBMCs
for 3–12 mo after infusion (Fig. 3). From our knowledge of
the transduction efficiency and the number of the CTLs in-
fused, we calculated that the levels of the neo gene in pe-
ripheral blood implied that marked T cells had expanded
up to at least 100-fold in vivo. For example, patient 1 re-
ceived a total CTL dose of 8   107 CTLs, of which 1.6%
were gene marked (1.28   106). His lymphocyte count
was 6% of the total white cell count (6,700/mm3). If we as-
sume that the CTLs remained in the peripheral blood,
which has a volume of approximately 5,000 ml, this would
give a total of 8   109 total mononuclear cells, of which
1.63% (1.28   108) were gene marked at 9 wk after the
CTLs. This equates to a 100-fold expansion (Fig. 3).
The above assessment likely profoundly underestimates
the true level of expansion because it assumes that all in-
fused CTLs remain in the circulation and do not enter lym-
phoid organs or tumor sites. In fact, marked T cells readily
leave the circulation, as shown in Fig. 4, in which an anal-
ysis of postmortem tissues from patient 4 using in situ PCR
showed gene-marked cells infiltrating a site of disease. Fur-
ther evidence that the CTL lines traffic and accumulate at
tumor sites came from patient 3. Q-PCR amplification
Figure 1. All CTL lines generated were polyclonal with unique V  repertoires. To analyze the V  repertoires of the CTL lines generated from six patients
(gray) and six normal donors (shaded), the CTLs were stained with anti-CD3 and 24 V  antibodies grouped into 8 vials. Surface immunofluorescence
was analyzed by flow cytometry.
Figure 2. EBV-specific CTL lines derived from Hodg-
kin patients and normal donors contained LMP2-specific
T cell populations on tetramer analysis. The frequency of
LMP2-specific T cells in CTL lines generated from 11 pa-
tients with relapsed HD were compared with CTL lines
from 7 normal donors with relevant HLA alleles. CTLs were
costained with PE-conjugated tetramers and FITC-conju-
gated CD8 and PerCP-conjugated CD3. Tetramers used
to test the lines were as follows: HLA-A02*01-CLG-
GLLTMV, HLA-A02*01-FLYALALLL, HLA-A11*01-
SSCSSCPLSKI, HLA-A23*01-PYLFWLAAI, HLA-A24-
TYGPVFMSL, and HLA-B35*01-MGSLEMVPM. The
average (  SD) of the results obtained from the normal
donor lines are shown in black compared to the results ob-
tained from each Hodgkin line tested, which are shown in
gray.Cytotoxic T Cells for EBV  Hodgkin’s Disease 1628
analysis of his malignant pleural effusion 3 wk after CTL
infusion revealed that 0.65% of the cells were marked ver-
sus just 0.001% in the peripheral blood. Hence, infused ef-
fector–memory T cells can expand and persist in vivo and
will traffic to sites of HD.
The Frequencies of EBV- and LMP2-specific T Cells Increase 
after Infusion of Polyclonal EBV-specific CTLs
Having shown an increase in the overall number of in-
fused gene-marked CTLs, we next determined whether
peripheral blood and tumor sites also showed the expected
corresponding increase in the frequency of EBV- and
LMP2-specific cells. LMP2 tetramer analysis of CD8  T
cells in the peripheral blood of the four HLA-A2 patients
showed a 2–20-fold increase for up to 9 mo after infusion
(Fig. 5 A). As argued for the measurement of gene-marked
CTLs in the circulation, this increase indicates a several log
expansion of the infused LMP2-specific cells in vivo be-
cause such small numbers of LMP2-specific T cells were
infused (Fig. 2).
In six patients for whom LMP2 peptide tetramer re-
agents were lacking, we used ELISPOT assays to measure
IFN-  release by CD8  CTLs after stimulation with autol-
ogous LCLs. This measure of EBV-specific CTL precursor
frequency showed a 1.3–4-fold increase in LCL-reactive
cells by 4 wk after infusion (Fig. 5 B). Because these exper-
iments gave no information about the LMP2-specific com-
ponent, we further studied two of these patients by mea-
suring IFN-  secretion by CD8  T cells after stimulation
with LMP2 peptide–pulsed PHA blasts in ELISPOT assays.
As shown in Fig. 5 C, there was a 2.5-fold increase in IFN- 
SFCs in response to the B35-restricted LMP2 peptide
MGS 8 wk after CTL infusion in patient 11, whereas pa-
tient 12 had a fourfold rise in the response to the HLA-
A11–restricted LMP2 peptide SSC (Fig. 5 D). These data
show that there is an increase in LMP2-specific CTLs in
vivo after infusion of small numbers of ex vivo–cultured
cells, and the infused cells are functional.
To demonstrate that this rise in LMP2-specific cells did
not simply parallel the general tempo of immune recovery
after SCT, we analyzed the response to irrelevant antigens.
As shown in Fig. 5 (C and D), the frequency of CMV and
superantigen-specific T cells failed to show the same in-
crease as the LMP2-specific T cells, suggesting that the in-
crease was specific to the infused T cells. Moreover, the V 
phenotype of the LMP2 tetramer  T cells in the peripheral
blood detected after infusion in patient 11 matches the
LMP2 tetramer  cells in the infused CTL line, further sup-
porting the assertion that the rise in LMP2-specific T cells
is attributable to the infused CTLs rather than to a general-
ized tide of immune recovery (Fig. 5 E). Finally, expansion
of LMP2-specific T cells in the peripheral blood can be ac-
companied by selective expansion or accumulation at tu-
mor sites because analysis of the malignant pleural effusion
from patient 3 showed a higher proportion of LMP2-spe-
cific T cells in effusion than in peripheral blood (Fig. 5 F).
EBV-specific CTLs Have Antiviral Activity in Patients with 
Relapsed HD
To determine if the infused CTLs had biological activity
after transfer, EBV DNA levels in patient PBMCs were mea-
sured before and after CTL infusion using Q-PCR. 9 of 10
patients with measurable EBV DNA in PBMCs had a fall in
viral DNA within 8 wk of CTL infusion, and in 6 of these,
EBV DNA became undetectable. Amongst these six were the
Figure 3. Infused CTLs gene marked with the neomycin
resistance gene can persist in vivo for up to 12 mo. We
used Q-PCR to quantify the presence of the marker gene
DNA in PBMCs after CTL infusion in the patients who
received gene-marked cells. Control DNA was prepared
by diluting G1Na-transduced K-562 cells (one integrant
per cell) with nontransduced K-562 to give mixtures con-
taining 0.01–10% neo  cells. Therefore, results are re-
ported as a percent of neo  cells in PBMCs after infusion.
Figure 4. Infused CTLs can home to tumor sites. In situ PCR analysis
of a mediastinal Hodgkin tumor obtained at autopsy 2 mo after receiving
gene-marked EBV-specific CTLs demonstrates gene-marked, tumor-
infiltrating lymphocytes.Bollard et al. 1629
patients in whom a rise in LMP2-specific T cells could be di-
rectly established using peptides. Levels of EBV DNA fell as
the numbers of LMP2-specific cells increased and rose again
as LMP2-specific cells declined (Fig. 5, C, D, and G).
Although the decline in EBV DNA after CTL infusion
likely reflects the killing of virus-infected normal B cells
rather than of tumor cells, it may nonetheless be a surrogate
marker of LMP2 effector function. The pattern of latency
generally found in the peripheral blood of immunocompe-
tent patients is “type 0,” in which there is expression of
LMP2, EBERs, and low levels of EBNA1 (15). Because
EBNA1 is poorly presented by infected cells and EBERs
Figure 5. The frequency of EBV- and LMP2-specific T
cells increase after infusion of polyclonal EBV-specific
CTLs. (A) Tetramer analysis was used to compare the fre-
quency of LMP2-specific CTLs before and after infusion
in the four patients who were HLA-A02*01. The mean
number   SD of A02*01 tetramer  cells per 106 CD8  T
cells are shown before and after infusion. (B) In six patients
where tetramer reagents were not available or where sample
volumes were small, ELISPOT analysis was used to com-
pare the mean frequency of peripheral blood T cells
(  standard error) responding to LCLs by IFN-  secretion
before and after CTL infusion. (C) In patients 11 and (D)
12 where the HLA-restricted LMP2 peptide was known, pe-
ripheral blood T cells were incubated with LMP2 peptide–
pulsed PHA blasts (black diamond) or CMV lysate/PHA
blasts pulsed with CMV peptide (gray triangle) or superan-
tigen (gray square). The number of IFN-  SFCs per 106 mono-
nuclear cells was measured. The average IFN-  SFCs  
standard error in response to the B35-restricted LMP2
peptide MGS before and after CTL infusion in patient 11
are shown in C, whereas the LMP2 peptide  populations
before and after CTL measured with the HLA-A11–restricted
LMP2 peptide SSC in patient 12 are shown in D. (E) The
V  phenotype of the PE-labeled LMP2 tetramer  T cells
from patient 11 were analyzed by flow cytometry using
available FITC-labeled V  antibodies in the infused CTL
line (black stripes) and were compared to the phenotype of
peripheral blood LMP2 tetramer  cells obtained before
(black bars) and 6 wk (gray bars) after CTL infusion. (F) In
the patient who had a partial response (patient 3), gene-
marked cells were detected in the pleural effusion at the
level of 0.65% using Q-PCR. A sample of this patient’s
pleural fluid was also tested for the presence of LMP2-specific
CTLs using the HLA-A02*01 tetramer CLG. As shown in
F, 1.21% of the patient’s CTL line was positive for this
tetramer, and these LMP2 tetramer–specific CTLs were
detected in the pleural fluid at a level three times higher
than that in the peripheral blood. (G) The EBV DNA
levels as determined by Q-PCR for patients 11 (black) and
12 (gray).Cytotoxic T Cells for EBV  Hodgkin’s Disease 1630
have no protein product, the presumptive target antigen for
the CTL is LMP2. A decrease in the peripheral blood EBV
DNA levels may thus indicate LMP2-specific cytolytic ac-
tivity in the infused CTL.
Toxicity and Clinical Outcomes
No toxicities were observed immediately after CTL in-
fusion, although two patients with measurable disease de-
veloped transient flu-like symptoms. One patient with
bulky mediastinal disease died from an erosion of the tumor
through the left upper lobe bronchus 3 mo after receiving
CTLs. We do not believe this was a toxicity due to CTL
infusion because in situ PCR for the marker gene showed
no gene-marked CTLs at the site of erosion, although foci
of gene-marked T cells were detected in other areas of dis-
ease (Fig. 4).
Clinical responses became evident within weeks of CTL
infusion and were observed in the patient group who had
clinical and radiological evidence of progressive/relapsed (as
opposed to stable) disease before CTL infusion (Table I).
Three of four patients had resolution of their B symptoms
(fever, night sweats, and weight loss; reference 22). Of the
11 patients with measurable tumor, 3 were evaluated as no
response to CTLs, 5 as stable disease, and 1 as a partial re-
sponse. Two patients, however, had complete responses to
therapy. The first of these (patient 14) was initially diag-
nosed with chronic active EBV infection. 2 yr later, she de-
veloped an enlargement of the mediastinum with suspected
hyperplasia of the thymus. Secondary EBV  Hodgkin lym-
phoma (mixed cellularity type) was diagnosed (stage IIA).
Over a 3-mo period, she received chemotherapy according
to the German HD 95 protocol (28) followed by fraction-
ated radiotherapy (19.8 Gy) for 6 wk. After this therapy, re-
sidual cervical lymphadenopathy persisted. She then devel-
oped rising EBV DNA levels. Her EBV IgM was negative
and she did not have clinical or laboratory evidence of in-
fectious mononucleosis. Biopsy results remained consistent
with EBV  HD. She received no other therapy until receiv-
ing two doses of EBV CTLs (total cell dose of 1.2   108/m2),
which were given 9 mo after completing the course of
radiotherapy. 4 wk after the first CTL infusion, the cervical
nodes became swollen and painful. A biopsy performed at
this time showed a prominent infiltrate of CD8  T cells and
a marked decrease in LMP1  (and EBER ) tumor cells as
Figure 6. Tumor responses. (A) In patient 14 whose cervical lymph nodes responded
to infusion of CTLs that were not genetically marked, immunohistochemical analysis re-
vealed CD8  tumor-infiltrating lymphocytes only after CTL infusion. This corresponded to
the disappearance of LMP1  cells. (B) A gallium scan demonstrating increased hilar up-
take is observed in patient 12 3 mo after autologous SCT. The follow-up scan 6 wk after
CTL infusion is reported as normal. (C) To demonstrate LMP2 specificity within patient
12’s infused CTL line in vitro, the frequency of CTLs specific for the HLA-A11–restricted
LMP2 epitope SSC was assessed using tetramer and (D) ELISPOT analysis, the latter using
SSC peptide–pulsed PHA blasts as targets. (E) Further, the percent-specific 51Cr release was
determined 6 h after coincubation with HLA-A11–matched fibroblasts transduced with
Ad5LMP2 (gray triangle) or Ad5GFP (gray square) and autologous LCLs (black dia-
mond). The percent-specific lysis at the indicated effector/target ratios for the EBV CTL
line from patient 12 is shown.Bollard et al. 1631
compared to the pre-CTL biopsy sample (Fig. 6 A). The
nodes subsequently reverted to normal, and the patient is
currently disease free for  9 mo. In the second complete
response (patient 12), a persistently abnormal gallium scan
after autologous SCT resolved after CTL infusion, and the
patient remains in remission after  27 mo (Fig. 6 B). The
specificity of this patient’s CTL line could be mapped to the
known HLA-A11 LMP2 peptide SSC (Fig. 6, C and D),
and the line produced significant LMP2-specific killing
(20% Cr51 release at an E/T ratio of 40:1) of HLA-A11–
matched fibroblast targets expressing LMP2 (Fig. 6 E). Us-
ing this information, it was possible to track the SSC-spe-
cific population in the peripheral blood before and after
CTL infusion. As shown in Fig. 5 D, the clinical response
correlated with a rise in the LMP2-specific precursor fre-
quency in the peripheral blood.
An additional three patients who had no clearly measur-
able disease at the time of CTL infusion also remain disease
free (requiring no additional therapy after CTL) 10–40 mo
later (Table I and footnote).
Discussion
We have used LCL-activated, EBV-specific cytotoxic T
lymphocytes (EBV CTLs) to treat patients with multiply
relapsed HD. We have shown that it is possible to generate
from these patients polyclonal EBV-specific CTL lines
with an effector–memory phenotype containing clones
specific for the subdominant tumor antigen LMP2
expressed by the malignant Reed-Sternberg cells. Gene
marking showed that the infused cells further expanded by
two logs or more in vivo and persisted for up to 1 yr after
infusion, trafficking to tumor sites. It is likely that actual
expansion is greater than this estimate because the infused
T cells do not remain exclusively in the blood, circulating
as well throughout the lymphoid tissues and entering tu-
mor sites (as shown in Figs. 4 and 5 F). Therefore, estimates
based on measurement in the peripheral blood alone may
underestimate the total expansion of infused cells in vivo.
These CTLs appeared functional, reducing EBV DNA lev-
els in PBMCs and producing IFN-  ex vivo in response to
LMP2 peptides. EBV-specific CTLs were safe at the dose
levels used, and administration was followed by measurable
tumor responses, including complete remissions.
Successful prevention and eradication of EBV lympho-
mas after transplant indicates that EBV CTLs can correct an
underlying EBV-specific immunodeficiency state and erad-
icate even bulky EBV antigen–expressing tumor cells (3).
Because in situ hybridization studies have localized EBV
RNA and antigens to the neoplastic Reed-Sternberg cells
in about 40% of cases of HD (29–31), it has been postu-
lated that EBV CTL therapy might also be of value in this
group of patients. However, most posttransplant lympho-
mas express the full panoply of EBV-associated latency an-
tigens, whereas EBV  Hodgkin tumors express a much
more restricted array, including LMP1, LMP2, EBNA1,
and perhaps proteins derived from the BamHI A region of
the viral genome (type 2 latency; references 30 and 32). Of
these antigens, LMP1 and LMP2 are weakly immunogenic,
whereas EBNA1 might be presented poorly to CD8  cyto-
toxic T cells (33–35). LMP1-specific T cells are rarely de-
tected in EBV CTLs (36) and indeed we did not detect
LMP1-specific T cells in any of our lines using known tet-
ramers. Although LMP2 is also considered weakly immu-
nogenic, the majority of the lines we tested using tetramer
or ELISPOT analysis contained cells with specificity for
this antigen. We were able to demonstrate that infusion of
CTLs was followed by in vivo expansion of both the total
numbers of EBV CTLs (measured by levels of gene mark-
ing) and the specific fraction that were LMP2 specific
(measured by tetramer or ELISPOT analysis). The LMP2–
specific T cells were functional in vitro, responding to
LMP2-expressing target cells and LMP2 peptides. They
also appeared active in vivo because their administration
was associated with a decrease in circulating EBV-infected
B cells, whose only CTL target antigen appears to be
LMP2 (15, 37). Although LMP1  tumor cells disappeared
after CTL infusion (Fig. 6 A), we believe this event to be
secondary to the activity of LMP2-specific effector cells,
rather than to cryptic LMP1 activity in the infused line.
The gene-marked CTLs were able to traffic to sites of
tumor, as were LMP2-specific T cells. Although we cannot
directly demonstrate that the infused LMP2-specific CTLs
were the cause of the tumor responses observed, the evi-
dence supports such a linkage. For example, patient 12 had
normalization of a gallium-67 scintigraphy scan within 8
wk of receiving CTL therapy (Fig. 6 B), and this patient’s
CTL line showed LMP2 specificity (Fig. 6, C–E). Normal-
ization of the scan occurred as he developed a rise in LMP2
peptide–specific T cells (measured by an IFN-  ELISPOT;
Fig. 5 D) and a fall in EBV DNA levels (Fig. 5 G). Simi-
larly, in patient 3 who had a partial response to CTL ther-
apy, in vivo expansion followed by selective accumulation
of gene-marked cells and LMP2 tetramer  cells at a site of
disease was followed by a partial disease response (Fig. 5 F).
Patients with EBV  HD are able to control their EBV-
infected normal B cells and epithelial cells without diffi-
culty. Therefore, it is paradoxical that their apparently im-
munogenic tumors coexist with circulating T cells with
specificity for the tumor antigens. It is not obvious why T
cells that were previously ineffectual in vivo should be-
come more active when reinfused as small numbers of ef-
fector–memory cells after ex vivo activation. We suggest
that endogenous LMP2-specific T cells are prevented from
exerting their potential effector function by the multiple
immunoregulatory strategies adopted by Hodgkin Reed-
Sternberg cells (9, 38). Hodgkin Reed-Sternberg cells
secrete immunosuppressive cytokines such as IL-10 and
TGF- , as well as the chemokine TARC, which selec-
tively recruits IL-4–secreting Th2 cells, thereby inhibiting
the Th1 cell CTL response (9, 39). Hodgkin Reed-Stern-
berg cells also recruit CD4 25  negative regulatory T cells
into the tumor environment (40). Removal of LMP2-spe-
cific T cells from this immunoregulatory environment mayCytotoxic T Cells for EBV  Hodgkin’s Disease 1632
allow the activation and expansion of this previously inhib-
ited population as well as completion of ex vivo–initiated
expansion and effector programs, even after the lympho-
cytes have been returned to an inhibitory environment.
However, it is likely that even infused CTLs may become
subject to tumor inhibition, reducing their effectiveness.
Although the results we report show that our adoptively
transferred T cells had biologic activity and could induce
even complete tumor responses, they also reveal limitations
with the current approach. Three patients with bulky dis-
ease showed no response at all, and in several of the re-
maining patients with measurable disease, response was
limited and transient. Nonetheless, given the difficulty of
treating relapsed EBV  HD and the toxicities associated
with conventional therapy, our observations support fur-
ther development of CTL therapy for this lymphoma and
perhaps for other weakly immunogenic tumors as well.
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